PVC景气回暖有望提振助剂需求，这些品种已率 先开启涨价；SpaceX计划在月球电磁弹射卫星， 技术路径有望加速得到产业验证——0301脱水研 报 2026/03/01 17:58 今日研报内容： 【本文来自持牌证券机构，不代表平台观点，请独立判断和决策】 摘要： 1、PVC：乙酰丙酮从底部1.3万元/吨涨至2.0万元/吨，其他助剂品种亦有望复制乙酰丙酮盐 的价格修复路径，实现企稳回升，迎来阶段性修复机遇。核心公司：键邦股份、瑞丰高材、 日科化学、新华制药。 2、草甘膦：天风证券研报指出，2月18日，特朗普签署了一份援引《国防生产法》的行政命 令，将元素磷和草甘膦类除草剂列为国防关键物资。美国国内草甘膦供应能力有限，对我国 进口依赖度仍较高，当前国内草甘膦价格处于较低水平。标的：扬农化工、兴发集团。 3、卫星制造：国泰海通证券研报指出，马斯克旗下SpaceX公司计划在月球表面通过巨型电 磁弹射装置发射卫星，以实现100万卫星的太空AI数据中心星座组网，国内火箭技术有望加速 迭代，利好卫星制造、火箭发射等产业链。标的：臻镭科技、铂力特。 4、煤炭：交易面与基本面共振，看好煤炭板块投资机会，把握三条主线：煤炭"高 ...

齐鲁晚报.齐鲁壹点樊伟宏 对于一家拥有80余年历史的红色药企而言，科研不仅是发展的速度，更是生命的厚度。 当时间的指针拨向2026年2月底，山东新华制药（000756）股份有限公司(简称"新华制药")一年一度的"新春科研座谈会"如期而至。若将镜头拉长，回看自 2024年、2025年直至今日的几场座谈会，会发现这面映照企业科研生态的镜子，既映照出不变的初心，也折射出时代的流变。 这种氛围的延续，源于新华制药骨子里对技术的敬畏。从1943年胶东抗日根据地一路走来，科技兴企不是挂在墙上的标语，而是刻在基因里的信条。每年 新春伊始，将科研人员奉为"座上宾"，正是这家老牌药企在激烈的行业竞争中保持战略定力的秘诀。 质变 如果说"尊重科研"是永恒的基调，那么会议桌上的核心议题，则在短短三年间发生了深刻的变化。 将视线拉远，新华制药这三年座谈会氛围的微妙变化，与整个中国制药行业的跌宕起伏紧密相连。 在"同"与"不同"的交织中，新华制药2026年的发展路径，正逐渐清晰。 不变的"C位" 如果将2024年、2025年及2026年的参会名单并列铺开，一个显著的"同"跃然纸上。 无论是2024年2月中下旬，还是2025年2月初，抑 ...

2026 年 02 月 27 日 基础化工 PVC 困境反转，助剂行业有望同步受益 本轮景气修复 事件： PVC 困境反转，开年以来价格持续上行，根据百川盈孚，截至 2026 年 2 月 25 日，PVC 市场价格 4547 元/吨，较年初上涨 6.8%。 PVC 景气回暖有望提振助剂需求： 2026 年以来，受"反内卷"政策持续深化、差别化电价试点逐步推行 以及出口退税政策取消等多重因素共同驱动，国内 PVC 市场景气度 稳步回升，价格整体呈现震荡上行态势。根据百川盈孚，截至 2026 年 2 月 25 日，PVC 价格为 4547 元/吨，较年初上涨 6.8%。作为 PVC 加工中不可或缺的关键材料，助剂在提升产品综合性能、优化加工工 艺与拓展应用场景等方面发挥着核心作用。随着 PVC 行情回暖，产业 链整体情绪或趋于积极，下游制品企业开工意愿有望增强，预计将带 动对高性能助剂的采购需求逐步释放，助剂行业有望同步受益于本轮 景气修复。 998948033 PVC 助剂体系丰富、品类众多： PVC 助剂涉及多个品类，其中重要的稳定剂包括乙酰丙酮盐、赛克、 DBM/SBM 等；重要的加工助剂及抗冲改性剂包括 ...

津巴布韦收紧锂精矿出口，供给扰动再现 [Table_Industry] 其他小金属 碳酸锂行业事件点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 李鹏飞(分析师) | 010-83939783 | lipengfei2@gtht.com | S0880519080003 | | 魏雨迪(分析师) | 021-38674763 | weiyudi@gtht.com | S0880520010002 | 本报告导读： 津巴布韦禁止锂精矿出口，在短期对全球锂的供给造成较大扰动，预期锂价偏强运 行。 [Table_Report] 相关报告 其他小金属《指标再度收紧，供给刚性挺价》 2025.04.23 其他小金属《开采指标下调，钨矿供应偏紧》 2024.03.20 投资要点： 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 股 票 研 究 行 业 事 件 快 评 股票研究 /[Table_Date] 2026.02.26 [Table_Summary] 维持"增持"评级。碳酸锂行业供给偏紧，库存持续去化，津巴布 韦禁 ...

证券日报网讯 2月10日，新华制药在互动平台回答投资者提问时表示，公司始终致力于心无旁骛发展医 药主业，努力为各利益相关方创造更多回报。 （文章来源：证券日报） ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - Xinhua Pharmaceutical has successfully obtained the necessary regulatory approval for its Glucosamine Sulfate Capsules, indicating a significant step in expanding its product offerings in the pharmaceutical market [1]

Group 1 - The European Central Bank (ECB) President Lagarde will discuss the EU economic situation and ECB activities on February 9, with Eurozone January CPI falling to 1.7% and core CPI to 2.2%, both below the ECB's 2% medium-term target [1] - The demand for electronic storage and CPU orders is surging, with capital expenditure and orders in the computing sector maintaining high growth, indicating a sustained improvement in industry conditions [1][15] Group 2 - The Shanghai Composite Index closed at 4123.09 points, up 1.41%, while the Shenzhen Component Index rose 2.17% to 14208.44 points, and the ChiNext Index increased by 2.98% to 3332.77 points, with total trading volume reaching 2.25 trillion [2] - The retail sector is experiencing a full recovery in travel demand during the Spring Festival, with flight bookings up 10% and hotel bookings increasing by over 15% [3] Group 3 - The beverage sales during the Spring Festival are strong, with notable growth in various brands, indicating a robust demand across food and beverage categories [5] - The high-end liquor market is stable, with significant growth in premium brands, while the real estate liquor segment is expected to see a turning point mid-year [6] Group 4 - The coal supply is tightening due to reduced export quotas from Indonesia, leading to a rapid increase in coal prices, which have rebounded from a low of $38 to $49.27 [6] - The high-end consumer market is gradually recovering, with a target of double-digit growth set for 2026, particularly in luxury and soft luxury segments [7] Group 5 - The new RWA regulations in Hong Kong clarify the non-monetary nature of virtual assets and define the path for RWA, with expectations for the secondary market to open in 2026 [8][9] - The home appliance market shows significant differentiation in sales performance, with black electronics and washing machines growing, while air conditioning and refrigerators decline [10][11] Group 6 - The demand for new energy sectors is increasing, with lithium carbonate prices at 130,000, and significant growth expected in sodium battery applications and wind power orders [13] - The computing-related industry is making significant progress, with Nvidia's quartz glass substrate samples being delivered and expected improvements in production efficiency [14] Group 7 - The overseas AI capital expenditure is surging, with major companies like AWS and Google significantly increasing their capital spending, driving demand across the AI supply chain [16][17] - The optical module market is experiencing rapid growth, with demand expected to double by 2026, particularly in data centers [20]

Core Viewpoint - Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of glucosamine sulfate capsule, which is classified as a Class 4 chemical drug and a Class A non-prescription drug, aimed at treating primary and secondary osteoarthritis [1] Group 1 - The glucosamine sulfate capsule is available in specifications of 0.25g or 0.314g [1] - The drug has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) as a Category B product [1]

Group 1: Zhejiang Longsheng - Zhejiang Longsheng announced a price increase for certain types of disperse dyes, with the price of disperse black rising by 5,000 yuan per ton recently [1] - The price adjustment is driven by the increase in the cost of reducing agents, which are important intermediates in dye production [1] - The company has a total dye production capacity of approximately 300,000 tons per year and a high degree of integration in its supply chain, which contributes to its competitive advantage [1] Group 2: Sanwei Biotech - Sanwei Biotech reported the final ruling of the U.S. Department of Commerce regarding anti-dumping and countervailing duties on erythritol from China, with a countervailing duty rate of 8.63% for the company [2] - The company did not qualify for a separate anti-dumping rate and faces a unified rate of 184.26%, which is a reduction from the initial ruling [2] - The overall effective tax rate for the company when exporting through specific channels is 93.58%, which may weaken its cost competitiveness in the U.S. market [2] Group 3: Zhiguang Electric - Zhiguang Electric's subsidiary signed a sales contract for energy storage systems worth 1.004 billion yuan, which is expected to positively impact the company's financial status and operational performance [3] Group 4: Yuanjie Technology - Yuanjie Technology plans to invest approximately 1.251 billion yuan to build a second phase of its optoelectronic communication semiconductor chip and device R&D and production base [4] - The project aims to enhance the company's market share and competitiveness in the global optical chip sector by expanding capacity and optimizing processes [4] Group 5: Jinhui Shares - Jinhui Shares announced a cash acquisition of 100% equity in Fusheng Mining for 210 million yuan, which includes mining rights for the Laoshengou gold mine with an annual production capacity of 50,000 tons [5] - The mine is located in a region with favorable geological conditions and high-grade gold resources [5] Group 6: Hainan Mining - Hainan Mining is planning to acquire 69.9% of Fengrui Fluorine Industry through a combination of issuing shares and cash payments, which will expand its fluorite mining business [6] - The company will issue shares to no more than 35 specific investors to raise matching funds for the acquisition [6] Group 7: Dingxin Communications - Dingxin Communications announced that its director and vice president was fined 120,000 yuan for engaging in short-term trading of the company's stock [7] Group 8: Mengguli - Mengguli plans to invest 929 million yuan to build a project for producing 30,000 tons of lithium-ion battery cathode materials annually, with a construction period of 36 months [8] - The project will be executed in two phases, with the first phase focusing on high-voltage lithium cobalt oxide and NCA materials [8] Group 9: Aifute - Aifute intends to acquire 100% of Shengpu Shares through a combination of share issuance and cash payment, with the stock set to resume trading [9] - Shengpu specializes in precision fluid control equipment, which is crucial for manufacturing processes in various industries [9] Group 10: Hengdian Film - Hengdian Film's stock experienced abnormal trading fluctuations, with a cumulative price increase of 83.98% over the past 10 trading days, indicating potential market overreaction [10] - The company warns of risks associated with a rapid decline in stock price due to significant deviations from its fundamental value [10] Group 11: Perfect World - Perfect World reported that its actual controller reduced holdings by 1.247 million shares during a period of abnormal stock price fluctuations [11] - The company confirmed that there were no significant changes in its operational environment or undisclosed information affecting stock prices [11] Group 12: Runtou Shares - Runtou Shares noted a recent price increase of approximately 5,000 yuan per ton for disperse black dyes, driven by rising prices of reducing agents [12] - The company operates in a highly competitive dye industry, with China being the largest producer and consumer of dyes globally [12]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]